Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates

J Control Release. 2015 Jul 28:210:147-59. doi: 10.1016/j.jconrel.2015.05.276. Epub 2015 May 19.

Abstract

Development of RNA-based antagonists (antimiRs) for disease-associated miRNAs in specific cell types or tissues has recently become a promising approach for treating several pathological conditions, including cancer. In order to explore the use of RNA-aptamers as carriers for cell-targeted delivery of antimiRs, here we designed two different conjugates using as carrier two aptamers that bind and antagonize cancer-associated receptor tyrosine kinases, Axl and PDGFRβ. We conjugated the tumor suppressor antimiR-222 to each aptamer demonstrating: 1) effective and selective delivery to receptor-expressing tumor cells, 2) increased expression of miR-222 target mRNAs, and 3) functional synergy between the kinase inhibitory aptamer and the antimiR antagonizing functions. Furthermore, we generated modular molecules in which two different antimiR sequences connected in tandem are conjugated to a unique carrier aptamer. We proved this strategy to be effective to deplete multiple microRNAs simultaneously, thus combining the effects of different antimiRs without losing the cell targeting specificity.

Keywords: AntimiR; Aptamer; Cancer; Targeted delivery; Therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / genetics
  • Animals
  • Aptamers, Nucleotide / administration & dosage*
  • Aptamers, Nucleotide / chemistry
  • Aptamers, Nucleotide / therapeutic use
  • Axl Receptor Tyrosine Kinase
  • Cell Line, Tumor
  • Humans
  • Interleukin-6 / genetics
  • Interleukin-8 / genetics
  • Liver / metabolism
  • Mice, Nude
  • MicroRNAs / antagonists & inhibitors*
  • Neoplasms / drug therapy
  • Neoplasms / pathology
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors*
  • Spleen / metabolism
  • Tumor Burden / drug effects

Substances

  • Aptamers, Nucleotide
  • Interleukin-6
  • Interleukin-8
  • MicroRNAs
  • Proto-Oncogene Proteins
  • interleukin-6, mouse
  • Receptor Protein-Tyrosine Kinases
  • Receptor, Platelet-Derived Growth Factor beta
  • 2',5'-Oligoadenylate Synthetase
  • Axl Receptor Tyrosine Kinase